Assessment of clinical outcomes of medicinal cannabis therapy for depression: analysis from the UK Medical Cannabis Registry

References

• Shumye S, Belayneh Z, Mengistu N. Health related quality of life and its correlates among people with depression attending outpatient department in Ethiopia: a cross sectional study. Health Qual Life Outcomes. 2019 Nov 8;17(1):1–9.
   PubMed Web of Science ®Google Scholar
• Osuch E, Marais A. The pharmacological management of depression. Dialogues Clin Neurosci. 2005;7(3):191–205.
   PubMedGoogle Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Apr 7;391(10128):1357–1366.
   PubMed Web of Science ®Google Scholar
• Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010 Jan 6;303(1):47–53.
   PubMed Web of Science ®Google Scholar
• Sharma T, Guski LS, Freund N, et al. Drop-out rates in placebo-controlled trials of antidepressant drugs: a systematic review and meta-analysis based on clinical study reports. Int J Risk Saf Med. 2019;30(4):217–232.
   PubMed Web of Science ®Google Scholar
• Serra G, Fratta W. A possible role for the endocannabinoid system in the neurobiology of depression. Clin Pract Epidemiol Ment Health. 2007 Nov 19;3(1):25.
   PubMedGoogle Scholar
• Lu HC, MacKie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016 Apr 1;79:516–525.
   PubMed Web of Science ®Google Scholar
• Wilkinson ST, Radhakrishnan R, D’Souza DC. A systematic review of the evidence for medical marijuana in psychiatric indications. J Clin Psychiatry. 2016 Aug;77:1050–1064.
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013;64:21–47.
   PubMed Web of Science ®Google Scholar
• Morcuende A, García-Gutiérrez MS, Tambaro S, et al. Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders. Front Psychiatry. 2022;13:866052.
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006 Jan;147(S1):S163–71.
   PubMedGoogle Scholar
• Laprairie RB, Bagher AM, Kelly ME, et al. Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor. Br J Pharmacol. 2015 Oct;172(20):4790–4805.
   PubMed Web of Science ®Google Scholar
• Deutsch DG. A Personal Retrospective: elevating Anandamide (AEA) by Targeting Fatty Acid Amide Hydrolase (FAAH) and the Fatty Acid Binding Proteins (FABPs). Front Pharmacol. 2016 Oct 13;7:370.
   PubMed Web of Science ®Google Scholar
• Sarris J, Sinclair J, Karamacoska D, et al. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry. 2020 Jan 16;20(1):24.
   PubMed Web of Science ®Google Scholar
• Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019 Dec 1;6(12):995–1010.
   PubMed Web of Science ®Google Scholar
• Allsop DJ, Copeland J, Lintzeris N, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry. 2014 Mar;71(3):281–291.
   PubMed Web of Science ®Google Scholar
• Podda G, Constantinescu CS. Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis. Expert Opin Biol Ther. 2012 Nov;12(11):1517–1531.
   PubMed Web of Science ®Google Scholar
• Trigo JM, Soliman A, Quilty LC, et al. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial. PLoS One. 2018 Jan 31;13(1):e0190768.
   PubMed Web of Science ®Google Scholar
• Aragona M, Onesti E, Tomassini V, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol. 2009 Feb;32(1):41–47.
   PubMed Web of Science ®Google Scholar
• Moreno JL L-S, García Caldentey J, Trigo Cubillo P, et al. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease. J Neurol. 2016 Jul;263(7):1390–1400.
   PubMed Web of Science ®Google Scholar
• Ball S, Vickery J, Hobart J, et al. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Health Technol Assess. 2015 Feb;19(12):1–187.
   Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005 Sep 27;65(6):812–819.
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004 Aug;10(4):434–441.
   PubMed Web of Science ®Google Scholar
• Weber M, Goldman B, Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1135–1140.
   PubMed Web of Science ®Google Scholar
• Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003 Nov 8;362(9395):1517–1526.
   PubMed Web of Science ®Google Scholar
• Wang Y, Jean Jacques J, Li Z, et al. Health outcomes among adults initiating medical cannabis for chronic pain: a 3-month prospective study incorporating Ecological Momentary Assessment (EMA). Cannabis. 2021 Oct;4(2):69–83.
   PubMedGoogle Scholar
• Fusar-Poli P, Allen P, Bhattacharyya S, et al. Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol. 2010 May;13(4):421–432.
   PubMed Web of Science ®Google Scholar
• Kudahl B, Berg ME, Posselt CM, et al. Medical cannabis and cannabis-based medicine show both potential efficacy and potential harms: cross-sectional comparison with controls on self-rated and interviewer-rated outcomes within the Danish pilot program on medical cannabis. Complement Ther Clin Pract. 2021 Nov;45:101476.
   PubMed Web of Science ®Google Scholar
• Abelev S, Warne LN, Benson M, et al. Medicinal cannabis for the treatment of chronic refractory pain: an investigation of the adverse event profile and health-related quality of life impact of an oral formulation. Med Cannabis Cannabinoids. 2022;5(1):20–31.
   PubMedGoogle Scholar
• Mazza M. Medical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series. J Cannabis Res. 2021 Feb 17;3(1):4.
   PubMedGoogle Scholar
• Cooke ME, Gilman JM, Lamberth E, et al. Assessing changes in symptoms of depression and anxiety during four weeks of cannabis abstinence among adolescents. Front Psychiatry. 2021;12:689957.
   PubMed Web of Science ®Google Scholar
• Bahorik AL, Leibowitz A, Sterling SA, et al. Patterns of marijuana use among psychiatry patients with depression and its impact on recovery. J Affect Disord. 2017;213:168–171.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Iorio G, Sepede G, et al. Cannabis use and psychosis: theme introduction. Curr Pharm Des. 2012;18(32):4991–4998.
   PubMed Web of Science ®Google Scholar
• Ricci V, Martinotti G, Ceci F, et al. Duration of untreated disorder and cannabis use: an observational study on a cohort of young Italian Patients Experiencing Psychotic Experiences and Dissociative Symptoms. Int J Environ Res Public Health. 2021;18(23):12632.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Lorio G, Tedeschi D, et al. Prevalence and intensity of basic symptoms among cannabis users: an observational study. Am J Drug Alcohol Abuse. 2011 Mar;37(2):111–116.
   PubMed Web of Science ®Google Scholar
• Fava M, Rankin MA, Wright EC, et al. Anxiety disorders in major depression. Compr Psychiatry. 2000 Apr;41(2):97–102.
   PubMed Web of Science ®Google Scholar
• Nutt D, Wilson S, Paterson L. Sleep disorders as core symptoms of depression. Dialogues Clin Neurosci. 2008 Sep 30;10(3):329–336.
   PubMedGoogle Scholar
• Almeida OP, Draper B, Pirkis J, et al. Anxiety, depression, and comorbid anxiety and depression: risk factors and outcome over two years. Int Psychogeriatr. 2012 Oct;24(10):1622–1632.
   PubMed Web of Science ®Google Scholar
• Franzen PL, Buysse DJ. Sleep disturbances and depression: risk relationships for subsequent depression and therapeutic implications. Dialogues Clin Neurosci. 2008;10(4):473–481.
   PubMedGoogle Scholar
• Bergamaschi MM, Queiroz RHC, Chagas MHN, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacol. 2011 May;36(6):1219–1226.
   PubMed Web of Science ®Google Scholar
• Crippa JAS, Nogueira Derenusson G, Borduqui Ferrari T, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011 Jan;25(1):121–130.
   PubMed Web of Science ®Google Scholar
• Walsh JH, Maddison KJ, Rankin T, et al. Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo. Sleep. 2021 Nov 12;44(11):zsab149.
   PubMed Web of Science ®Google Scholar
• Nicholson AN, Turner C, Stone BM, et al. Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol. 2004 Jun;24(3):305–313.
   PubMed Web of Science ®Google Scholar
• Hser YI, Mooney LJ, Huang D, et al. Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. J Subst Abuse Treat. 2017;81:53–58.
   PubMed Web of Science ®Google Scholar
• Erridge S, Salazar O, Kawka M, et al. An initial analysis of the UK Medical Cannabis Registry: outcomes analysis of first 129 patients. Neuropsychopharmacol Rep. 2021 Sep;41(3):362–370.
   PubMed Web of Science ®Google Scholar
• Von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ. 2007 Nov;85(11):867–872.
   PubMed Web of Science ®Google Scholar
• Case P. The NICE guideline on medicinal cannabis: keeping pandora’s box shut tight? Med Law Rev. 2020 May 1;28(2):401–411.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of the US National Cancer Institute’s Patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol. 2015 Nov;1(8):1051–1059.
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606–613.
   PubMed Web of Science ®Google Scholar
• Spitzer RL, Kroenke K, Williams JBW, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092–1097.
   PubMed Web of Science ®Google Scholar
• Snyder E, Cai B, DeMuro C, et al. A new single-item sleep quality scale: results of psychometric evaluation in patients with chronic primary insomnia and depression. J Clin Sleep Med. 2018 Nov 15;14(11):1849–1857.
   PubMed Web of Science ®Google Scholar
• Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–1736.
   PubMed Web of Science ®Google Scholar
• Johnson SU, Ulvenes PG, Øktedalen T, et al. Psychometric properties of the general anxiety disorder 7-item (GAD-7) scale in a heterogeneous psychiatric sample. Front Psychol. 2019;10:1713.
   PubMed Web of Science ®Google Scholar
• Van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012 Jul-Aug;15(5):708–715.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Position statement on use of the EQ-5D-5L value set for England 2019 [ updated October 2019; cited 2022 Jul 11th]. Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l
   Google Scholar
• Ferguson L, Scheman J. Patient global impression of change scores within the context of a chronic pain rehabilitation program. J Pain. 2009;10(4):S73.
   Google Scholar
• McMillan D, Gilbody S, Richards D. Defining successful treatment outcome in depression using the PHQ-9: a comparison of methods. J Affect Disord. 2010 Dec;127(1–3):122–129.
   PubMed Web of Science ®Google Scholar
• Round JM, Lee C, Hanlon JG, et al. Changes in patient health questionnaire (PHQ-9) scores in adults with medical authorization for cannabis. BMC Public Health. 2020 Jun 23;20(1):987.
   PubMed Web of Science ®Google Scholar
• Martin EL, Strickland JC, Schlienz NJ, et al. Antidepressant and anxiolytic effects of medicinal cannabis use in an observational trial. Front Psychiatry. 2021 Sep 9;12:729800.
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983 Jun;67(6):361–370.
   PubMed Web of Science ®Google Scholar
• Patton GC, Coffey C, Carlin JB, et al. Cannabis use and mental health in young people: cohort study. BMJ. 2002 Nov 23;325(7374):1195–1198.
   PubMed Web of Science ®Google Scholar
• Hengartner MP, Angst J, Ajdacic-Gross V, et al. Cannabis use during adolescence and the occurrence of depression, suicidality and anxiety disorder across adulthood: findings from a longitudinal cohort study over 30 years. J Affect Disord. 2020 Jul 1;272:98–103.
   PubMed Web of Science ®Google Scholar
• Lucatch AM, Kloiber SM, Meyer JH, et al. Effects of extended cannabis abstinence in major depressive disorder. Can J Addict. 2020;11(3):33–41.
   Web of Science ®Google Scholar
• Li H, Ge S, Greene B, et al. Depression in the context of chronic diseases in the United States and China. Int J Nurs Sci. 2018 Nov 29;6(1):117–122.
   PubMed Web of Science ®Google Scholar
• Hill M, Gorzalka B. The endocannabinoid system and the treatment of mood and anxiety disorders. CNS Neurol Disord Drug Targets. 2009 Dec;8(6):451–458.
   PubMed Web of Science ®Google Scholar
• Zbozinek TD, Rose RD, Wolitzky-Taylor KB, et al. Diagnostic overlap of generalized anxiety disorder and major depressive disorder in a primary care sample. Depress Anxiety. 2012 Dec;29(12):1065–1071.
   PubMed Web of Science ®Google Scholar
• Colizzi M, Bhattacharyya S. Cannabis use and the development of tolerance: a systematic review of human evidence. Neurosci Biobehav Rev. 2018;93:1–25.
   PubMed Web of Science ®Google Scholar
• Rapin L, Gamaoun R, El Hage C, et al. Cannabidiol use and effectiveness: real-world evidence from a Canadian medical cannabis clinic. J Cannabis Res. 2021 Jun 23;3(1):19.
   PubMedGoogle Scholar
• Rock EM, Bolognini D, Limebeer CL, et al. Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol. 2012;165:2620–2634.
   PubMed Web of Science ®Google Scholar
• Silvestro S, Schepici G, Bramanti P, et al. Molecular targets of cannabidiol in experimental models of neurological disease. Molecules. 2020 Nov 7;25:5186.
   PubMed Web of Science ®Google Scholar
• Papagianni EP, Stevenson CW. Cannabinoid regulation of fear and anxiety: an update. Curr Psychiatry Rep. 2019 Apr 27;21:38.
   PubMed Web of Science ®Google Scholar
• Schlienz NJ, Scalsky R, Martin EL, et al. A cross-sectional and prospective comparison of medicinal cannabis users and controls on self-reported health. Cannabis Cannabinoid Res. 2021;6:548–558.
   PubMedGoogle Scholar
• Ergisi M, Erridge S, Harris M, et al. An updated analysis of clinical outcome measures across patients from the UK Medical Cannabis Registry. Cannabis Cannabinoid Res. 2022 Jan 24 [cited 2022 Aug 3]. Avilable from: https://doi.org/10.1089/can.2021.0145
   PubMedGoogle Scholar
• Ergisi M, Erridge S, Harris M, et al. UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder. Expert Rev Clin Pharmacol. 2022;18:1–9.
   Google Scholar
• Harris M, Erridge S, Ergisi M, et al. UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions. Expert Rev Clin Pharmacol. 2021;31:1–13.
   Google Scholar
• Wang T, Collet JP, Shapiro S, et al. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008 Jul 17;178:1669–1678.
   PubMed Web of Science ®Google Scholar
• Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 2010 Oct 5;182:E694–701.
   PubMed Web of Science ®Google Scholar
• Andreae MH, Carter GM, Shaparin N, et al. Inhaled cannabis for chronic neuropathic pain: an individual patient data meta-analysis. J Pain. 2015;16:1221–1232.
   PubMed Web of Science ®Google Scholar
• Hazekamp A, Ware MA, Muller-Vahl KR, et al. The medicinal use of cannabis and cannabinoids—an international cross-sectional survey on administration forms. J Psychoactive Drugs. 2013;45:199–210.
   PubMed Web of Science ®Google Scholar
• Finniss DG, Kaptchuk TJ, Miller F, et al. Placebo effects: biological, clinical and ethical advances. Lancet. 2010 Feb 20;375:686–695.
   PubMed Web of Science ®Google Scholar
• Akobeng AK. Understanding randomised controlled trials. Arch Dis Child. 2005 Aug;90:840–844.
   PubMed Web of Science ®Google Scholar
• Hindocha C, Brose LS, Walsh H, et al. Cannabis use and co-use in tobacco smokers and non-smokers: prevalence and associations with mental health in a cross-sectional, nationally representative sample of adults in Great Britain, 2020. Addiction. 2021;116:2209–2219.
   PubMed Web of Science ®Google Scholar
• Salk RH, Hyde JS, Abramson LY. Gender differences in depression in representative national samples: meta-analyses of diagnoses and symptoms. Psychol Bull. 2017 Aug;143(8):783–822.
   PubMed Web of Science ®Google Scholar